Clinical Trial Results: Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating grass pollen immunotherapy combined with dupilumab for tolerance induction in allergic rhinoconjunctivitis and grass pollen allergy. Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis
• Grass Pollen Allergy

Drugs mentioned

• Dupilumab (dupilumab)
• Grass pollen immunotherapy

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Allergic Rhinoconjunctivitis, Grass Pollen Allergy | Phase 2 | Status: COMPLETED | Results posted: 2026-04-27